Liang-liang Ding

Jingzhou, 434000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials.

Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials.

Journal: Endocrine journal

Published: May 24, 2021

Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs.

Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs.

Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions

Published: May 14, 2021

Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF.

Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF.

Journal: Cardiovascular drugs and therapy

Published: May 13, 2021

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors.

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors.

Journal: Diabetes & vascular disease research

Published: April 23, 2021

Letter to the Editor regarding the article "SGLT2 inhibitors and cardiovascular and renal outcomes: a meta‑analysis and trial sequential analysis".

Letter to the Editor regarding the article "SGLT2 inhibitors and cardiovascular and renal outcomes: a meta‑analysis and trial sequential analysis".

Journal: Heart failure reviews

Published: April 14, 2021

Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM.

Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM.

Journal: Frontiers in cardiovascular medicine

Published: April 03, 2021

Do all gliflozins reduce stroke in patients with type 2 diabetes mellitus and impaired renal function?

Do all gliflozins reduce stroke in patients with type 2 diabetes mellitus and impaired renal function?

Journal: Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

Published: March 18, 2021

Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: A meta-analysis of cardiovascular outcome trials.

Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: A meta-analysis of cardiovascular outcome trials.

Journal: Medicine

Published: February 28, 2021

SGLT2 inhibitors should be recommended in patients with one or more of the three diseases: type 2 diabetes, chronic kidney disease, and HFrEF.

SGLT2 inhibitors should be recommended in patients with one or more of the three diseases: type 2 diabetes, chronic kidney disease, and HFrEF.

Journal: European journal of internal medicine

Published: February 15, 2021

Commentary: Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Commentary: Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal: Frontiers in endocrinology

Published: February 05, 2021

Factors affecting the efficacy of SGLT2is on heart failure events: a meta-analysis based on cardiovascular outcome trials.

Factors affecting the efficacy of SGLT2is on heart failure events: a meta-analysis based on cardiovascular outcome trials.

Journal: Cardiovascular diagnosis and therapy

Published: December 06, 2020

Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors.

Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors.

Journal: Endocrine

Published: November 07, 2020

Showing 1-12 of 21

Last Updated: 09/26/2026